Correlation ID'd for Low Maternal B12, Higher Leptin

This article originally appeared here.
Share this content:
Correlation ID'd for Low Maternal B12, Higher Leptin
Correlation ID'd for Low Maternal B12, Higher Leptin

MONDAY, Nov. 7, 2016 (HealthDay News) -- Low maternal B12 is associated with higher leptin in cord blood, maternal adipose tissue, and placental tissue, according to a study presented at the annual meeting of the Society for Endocrinology, held from Nov. 7 to 9 in Brighton, U.K.

Antonysunil Adaikalakoteswari, from the University of Warwick in the United Kingdom, and colleagues collected paired maternal venous and cord blood samples (91 samples), adipose tissue (42 samples), and placental tissue (83 samples) at delivery. They determined serum vitamin B12 and measured leptin levels. Human pre-adipocyte cell line was differentiated in various B12 concentrations (control, low B12, and control plus methylation inhibitor) to assess the underlying mechanism.

The researchers found that B12 deficiency was common, seen in 40 percent of mothers and 29 percent of neonates. After adjustment for likely confounding variables, there was an independent correlation between maternal B12 and neonatal leptin (P = 0.002). Mothers with low B12 had higher leptin gene expression in adipose tissue and placental tissue. Adipocytes cultured with low B12 and treated with normal B12 in the presence of methylation inhibitor had higher leptin gene expression.

"The leptin can increase for two reasons," Adaikalakoteswari said in a statement. "Either low B12 drives fat accumulation in the fetus, and this leads to increased leptin, or the low B12 actually causes chemical changes in the placental genes that produce leptin, making more of the hormone."

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

FDA OKs Lynparza to Treat Breast Cancer With BRCA Mutation

FDA OKs Lynparza to Treat Breast Cancer With ...

PARP inhibitor therapy already approved to treat BRCA-mutated ovarian cancer

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Ceramide-Infused Skin Barrier Cuts Stoma-Related Costs

Use of ceramide-infused barrier tied to lower stoma-related care costs, improved patient satisfaction

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-Ventilator Hospital-Acquired Pneumonia Risk Affects All Ages

Non-vent-associated HAP risk occurs in all hospital units; risk extends even to low-risk/younger patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »